Interim Clinical Results for VTP-1000, an IM-Administered ASIT Therapy for Celiac Disease

• SNAP-TI is an ASIT platform that enables co-delivery of multiple unique peptide antigens and rapamycin in nanoparticles of precise size and composition for local (IM or SC) administration
• VTP-1000 is a candidate for celiac disease based on SNAP-TI
• Updates on the VTP-1000 clinical program including safety and immunology parameters will be presented

Speakers:

Geoffrey Lynn

Advisor & ASIT Program Scientific Lead, Chief Scientific Officer

Barinthus Biotherapeutics